REHABILITATION INSTITUTE OF CHICAGO
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 1954-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.ric.org/
Clinical Trials
168
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (148 trials with phase data)β’ Click on a phase to view related trials
Improving Walking After Spinal Cord Injury
- Conditions
- Spinal Cord Injury
- First Posted Date
- 2025-11-03
- Last Posted Date
- 2025-11-03
- Lead Sponsor
- Shirley Ryan AbilityLab
- Target Recruit Count
- 20
- Registration Number
- NCT07223710
- Locations
- πΊπΈ
Shirley Ryan AbilityLab, Chicago, Illinois, United States
Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain
- Conditions
- Multiple SclerosisNeurologic DisorderFibromyalgiaNeuromuscular Disorders
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Shirley Ryan AbilityLab
- Target Recruit Count
- 15
- Registration Number
- NCT07132775
- Locations
- πΊπΈ
Shirley Ryan AbilityLab, Chicago, Illinois, United States
Assessing Upper Extremity Function in Chronic Stroke Survivors Through Acute Intermittent Hypoxia
- Conditions
- Stroke
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Shirley Ryan AbilityLab
- Target Recruit Count
- 20
- Registration Number
- NCT07113457
WIM Exosuit Wearable Soft Robot for Enhancing Walking Activity
- Conditions
- StrokeHealthy
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Shirley Ryan AbilityLab
- Target Recruit Count
- 20
- Registration Number
- NCT07061691
- Locations
- πΊπΈ
Shirley Ryan AbilityLab, Chicago, Illinois, United States
Neuromusculoskeletal Interface for Bionic Arms
- Conditions
- AmputationAmputation, TraumaticAmputation, SurgicalUpper Limb Amputation Above Elbow (Injury)
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Shirley Ryan AbilityLab
- Target Recruit Count
- 12
- Registration Number
- NCT07032753
- Locations
- πΊπΈ
Shirley Ryan Abilitylab, Chicago, Illinois, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 34
- Next
News
Experimental Peptide Drug NVG-291 Shows Promise in Phase 2 Trial for Spinal Cord Injury Recovery
NVG-291, an injectable peptide drug, demonstrated significant mobility improvements in a phase 2 trial for spinal cord injury patients, with one participant reducing his 10-meter walk time from 45 to 15 seconds.
NervGen Pharma to Present Phase 1b/2a Trial of NVG-291 for Spinal Cord Injury at Upcoming Investor Event
NervGen Pharma will host a virtual investor event on April 9, 2025, featuring key opinion leaders to discuss the unmet medical needs and treatment landscape for spinal cord injury patients.